Table 1.
Baseline Demographic and Disease Characteristics
| Variables | RBZ + Laser N=77 | BVZ +Laser N=51 | p-value | |
|---|---|---|---|---|
| Age [years (Mean ± SD)] | 55.2±9.20 | 56 0.3±8.15 | 0.489 | |
| Gender | Male | 42 (54.54%) | 26 (50.98%) | 0.692 |
| Female | 35 (45.45%) | 25 (49.01%) | ||
| Duration of DM [years (Mean ± SD)] | 11.92±4.31 | 13.02±5.06 | 0.191 | |
| HbA1c (%) | 7.56±3.2 | 7.42 ±4.1 | 0.829 | |
| Diabetic retinopathy type | Moderate NPDR + focal DME | 40 (51.94%) | 25 (49.01%) | 0.801 |
| Severe NPDR+ diffused DME | 24 (31.16%) | 15 (29.41%) | ||
| PDR+ diffused DME | 13 (16.88%) | 11 (21.56%) | ||
Notes: Data were presented as mean ± SD. Normally distributed variables of two groups were compared by unpaired Student’s t-test. Not-normally distributed variables of the two groups were compared by the Mann–Whitney U-test. Categorical variables in two groups were presented as percentages (%) and compared by the Chi-Square test. The study showed no statistically significant difference in baseline demographic parameters. A value of p < 0.05 was considered statistically significant.
Abbreviations: RBZ, ranibizumab; BVZ, bevacizumab; DM, diabetes mellitus; HbA1c, glycated hemoglobin; NPDR, nonproliferative diabetic retinopathy; DME, diabetic macular edema; BCVA, best-corrected visual acuity; CMT, central macular thickness; IOP, intraocular pressure; SD, standard deviation.